TABLE 4.
Individual Management Changes
| Management change | Q1 to Q2 | Q2 to implemented | Q1 to implemented |
| Conversion to focal treatment/new focal treatment | 40 (40) | 14 (14) | 29 (29) |
| Active surveillance to surgery ± ADT | 5 (5) | 0 (0) | 5 (5) |
| Active surveillance to SRT ± ADT | 9 (9) | 2 (2) | 3 (3) |
| Active surveillance to SBRT ± ADT | 0 (0) | 0 (0) | 1 (1) |
| ADT to surgery ± ADT | 3 (3) | 0 (0) | 1 (1) |
| ADT to surgery + SRT + ADT | 0 (0) | 0 (0) | 1 (1) |
| ADT to SRT ± ADT | 4 (4) | 1 (1) | 2 (2) |
| ADT to SRT + CTx + ADT | 1 (1) | 0 (0) | 0 (0) |
| ADT to SBRT ± ADT | 4 (4) | 0 (0) | 4 (4) |
| ADT to SBRT + CTx + ADT | 0 (0) | 0 (0) | 1 (1) |
| CTx + ADT to surgery | 1 (1) | 0 (0) | 0 (0) |
| CTx + ADT to SRT ± ADT | 1 (1) | 1 (1) | 1 (1) |
| CTx + ADT to SBRT ± ADT | 1 (1) | 0 (0) | 2 (2) |
| PSMA-RNT to SRT + ADT | 0 (0) | 1 (1) | 0 (0) |
| SRT ± ADT to surgery | 5 (5) | 2 (2) | 2 (2) |
| SRT ± ADT to SBRT ± ADT | 5 (5) | 1 (1) | 5 (5) |
| SRT ± ADT to SBRT + SRT ± ADT | 0 (0) | 1 (1) | 1 (1) |
| SRT ± ADT to SBRT + CTx + ADT | 0 (0) | 1 (1) | 0 (0) |
| SRT + CTx + ADT to SBRT + ADT | 0 (0) | 1 (1) | 0 (0) |
| SBRT + ADT to surgery | 1 (1) | 0 (0) | 0 (0) |
| Surgery + ADT to SRT + ADT | 0 (0) | 2 (2) | 0 (0) |
| Surgery + ADT to surgery + SRT + ADT | 0 (0) | 1 (1) | 0 (0) |
| Conversion to systemic treatment | 12 (12) | 7 (7) | 13 (13) |
| Active surveillance to ADT | 4 (4) | 1 (1) | 4 (4) |
| Active surveillance to other systemic treatment + ADT | 0 (0) | 0 (0) | 3 (3) |
| Surgery ± ADT to ADT | 0 (0) | 3 (3) | 0 (0) |
| SRT + CTx ± ADT to ADT | 1 (1) | 0 (0) | 1 (1) |
| SRT ± ADT to ADT | 5 (5) | 2 (2) | 5 (5) |
| SRT ± ADT to CTx + ADT | 1 (1) | 0 (0) | 0 (0) |
| SBRT + ADT to other systemic treatment + ADT | 1 (1) | 1 (1) | 0 (0) |
| Unknown to ADT | 0 (0) | 0 (0) | 0 (0) |
| Conversion to active surveillance | 5 (5) | 7 (7) | 7 (7) |
| Surgery ± ADT to active surveillance | 0 (0) | 3 (3) | 0 (0) |
| SRT ± ADT to active surveillance | 4 (4) | 2 (2) | 4 (4) |
| SRT + CTx to active surveillance | 0 (0) | 0 (0) | 0 (0) |
| ADT to active surveillance | 1 (1) | 2 (2) | 3 (3) |
| Change in systemic treatment | 5 (5) | 7 (7) | 5 (5) |
| ADT to CTx ± ADT | 3 (3) | 0 (0) | 0 (0) |
| ADT to other systemic treatment ± ADT | 0 (0) | 4 (4) | 2 (2) |
| CTx ± ADT to ADT | 0 (0) | 3 (3) | 1 (1) |
| CTx + bone RNT + ADT to ADT + CTx | 0 (0) | 0 (0) | 0 (0) |
| CTx + bone RNT + ADT to CTx + PSMA-RNT + ADT | 0 (0) | 0 (0) | 0 (0) |
| CTx + bone RNT + ADT to PSMA-RNT | 1 (1) | 0 (0) | 1 (1) |
| Bone RNT + ADT to CTx + ADT | 1 (1) | 0 (0) | 1 (1) |
| Bone RNT + ADT to PSMA-RNT | 0 (0) | 0 (0) | 0 (0) |
| Total | 62 (61) | 35 (35) | 54 (53) |
ADT = androgen deprivation therapy; SRT = salvage radiation therapy; SBRT = stereotactic body radiation therapy; CTx = chemotherapy; RNT = radionuclide therapy.
Data are numbers followed by percentages in parentheses.